Pharma Focus Asia

Ono Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration

Tuesday, March 19, 2019

Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.

Under the agreement, twoXAR will use its proprietary AI technology to identify a set of lead compounds which demonstrate a novel mechanism of action and will be further optimized by Ono for potential drug candidates. twoXAR will also predict a set of hypotheses which suggest the efficacy and safety of such lead compounds for the therapy. twoXAR and Ono will select several compounds with their hypotheses from this set to test in further validation studies. Ono will retain exclusive rights to develop and commercialize the compounds obtained through this collaboration throughout the world, and in return, twoXAR will receive research and license fees from Ono as well as development and sales milestones.

“As we expand our portfolio of drug discovery programs through collaborations with experienced drug development teams, we are honored to enter this collaboration with Ono Pharmaceutical. Ono has a rich history in drug development, and our partnership represents their continual commitment to improve efficiency in R&D,” stated Andrew A. Radin, Co-Founder and CEO of twoXAR. “twoXAR continues to grow its drug development partnerships internationally and this collaboration with Ono represents our second with a globally-operating, Japan-headquartered partner.”

“We highly value twoXAR’s approach to help drug discovery because it enables rapid identification and in vitro and in vivo efficacy validation of new lead compounds,” said Toichi Takino, Corporate Officer Executive Director, Discovery & Research. “By combining Ono’s drug discovery experience and twoXAR’s AI technology, we believe that we can increase the speed and probability of success in discovering and developing innovative first-in-class drugs to expand our neurological disease pipeline.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024